CD8A and neoplasm: In GBM xenografts and intracranial tumor mouse models, they showed that inhibiting cPLA2 activity blocks tumor proliferation and prevents PTRF-induced reduction in CD8 TILs, thus suggesting cPLA2 as an attractive therapeutic target [154].